Date: 2015-01-12
Type of information: Collaboration agreement
Compound: SIMPLE Antibody™ platform
Company: Argen-X (Belgium) de Duve Institute (Université Catholique de Louvain - Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 12, 2015, arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases announced it has initiated its Innovative Access Program, providing its SIMPLE Antibody™ platform to academic centers of excellence and emerging biotech companies through collaboration. The goal of this program is to exploit the proven power of the SIMPLE Antibody™ platform in therapeutic areas complementary to arGEN-X’s strategic focus.
The first Innovative Access Program collaborations are with an unnamed US-based biotechnology company active in the field of dyslipidemia research and with the de Duve Institute (Université Catholique de Louvain - Belgium) in the field of cancer immunotherapy. The collaboration with the de Duve Institute (Université Catholique de Louvain – Belgium) was initiated for the use of the SIMPLE AntibodyTM platform and technical expertise of arGEN-X to validate a novel immune checkpoint target, GARP. arGEN-X will have the rights, following an upcoming predefined milestone, to exercise an option to exclusively in-license GARP-targeting antibodies for further development and commercialization as part of its proprietary product pipeline.
Financial terms:
Latest news:
